Enzon Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-3.41	0.78	1.37	-0.19	-0.47	Upgrade
Other Operating Activities	0.02	0.34	-0.16	-0.2	-	Upgrade
Change in Accounts Payable	-	-	-	-	0.03	Upgrade
Change in Other Net Operating Assets	0.38	0	0.09	-0.27	-0.06	Upgrade
Operating Cash Flow	-3.01	1.12	1.31	-0.66	-0.5	Upgrade
Operating Cash Flow Growth	-	-14.02%	-	-	-	Upgrade
Preferred Dividends Paid	-1.28	-1.28	-1.28	-	-	Upgrade
Dividends Paid	-1.28	-1.28	-1.28	-	-	Upgrade
Financing Cash Flow	-1.28	-1.28	-1.28	-	-	Upgrade
Net Cash Flow	-4.29	-0.15	0.03	-0.66	-0.5	Upgrade
Levered Free Cash Flow	-1.74	-0.83	-0.56	0.36	-0.33	Upgrade
Unlevered Free Cash Flow	-1.74	-0.83	-0.56	0.36	-0.33	Upgrade
Change in Working Capital	0.38	0	0.09	-0.27	-0.03	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.